Generic versus brand-name drugs used in cardiovascular diseases: an updated meta-analysis

L Manzoli, Me Flacco, Stefania Boccia, E D’Andrea, N Panic, C Marzuillo, R Siliquini, Walter Ricciardi, P Villari, Jp Ioannidis

Risultato della ricerca: Contributo in rivistaContributo a convegno


Besides bioequivalence, the crucial assumption of equal health benefits of generics and brand-name cardiovascular drugs is based upon a single meta-analyses, published in 2008, combining only efficacy outcomes, and basing its conclusions on antiplatelet agents, ACE inhibitors and statins upon 50, 23 and 71 subjects, respectively. Such a scarcity of randomized evidence is typically used to support periodic claims of a superior clinical effect of brand-name vs generic drugs.We performed a meta-analysis to compare the efficacy and safety of generic versus brand-name cardiovascular drugs.
Lingua originaleEnglish
pagine (da-a)74-74
Numero di pagine1
RivistaEuropean Journal of Public Health
Stato di pubblicazionePubblicato - 2015
Evento8th European Public Health Conference - Milano
Durata: 14 ott 201517 ott 2015


  • cardiovascular diseases
  • meta-analysis


Entra nei temi di ricerca di 'Generic versus brand-name drugs used in cardiovascular diseases: an updated meta-analysis'. Insieme formano una fingerprint unica.

Cita questo